fbpx

List – 44 Drug Patents that are Expiring in 2029

Last week we uncovered the list of drug patents expiring in 2028. But can highfliers like you and I stop at that?

Well, rest your numbing tendons for we’re here with the list of drug patents expiring in 2029. The list includes not just the drug names but also other information like yearly sales, treatment, ingredients, and the disease they cure which could help them (you) easily choose the drug most profitable to develop a generic version.

Without any delay, here is the list of drugs. Thank us later!

The article has a list of drug patents expiring in 2029. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.


Drug Patents Expiring in 2029

Lamictal Odt
Lamotrigine

More information about this Drug

Patents Expiration Date
US7919115 January 4, 2029

Dosage: Oral
Company: GlaxoSmithKline
Ingredients: LAMOTRIGINE
Treatment: Epilepsy

Wakix
Pitolisant

More information about this Drug

Patents Expiration Date
US8207197 February 25, 2029

Dosage: Oral
Company: Harmony Biosciences Llc
Ingredients: PITOLISANT HYDROCHLORIDE
Treatment: Excessive Daytime Sleepiness

Caplyta
Lumateperone

More information about this Drug

Patents Expiration Date
US9586960 March 12, 2029
USRE48825 March 12, 2029
US8648077 December 1, 2029

Dosage: Oral
Company: Intra-cellular Therapies Inc
Ingredients: LUMATEPERONE TOSYLATE
Treatment: Schizophrenia And Bipolar Depression

Desyrel
Trazodone

More information about this Drug

Patents Expiration Date
US8133893 March 13, 2029

Dosage: Oral
Company: Pragma Pharmaceuticals Llc
Ingredients: TRAZODONE HYDROCHLORIDE
Treatment: Major Depressive Disorder, Anxiety Disorders, and Difficulties With Sleep

Neuraceq
Florbetaben

More information about this Drug

Patents Expiration Date
US7807135 March 18, 2029

Dosage: Intravenous
Company: Life Molecular Imaging Ltd
Ingredients: FLORBETABEN F-18
Treatment: Alzheimer’s Disease

Monoferric
Ferric derisomaltose

More information about this Drug

Patents Expiration Date
US10414831 March 25, 2029
US8815301 August 14, 2029

Dosage: Intravenous
Company: Pharmacosmos As
Ingredients: FERRIC DERISOMALTOSE
Treatment: Iron Deficiency Anemia

Gemtesa
Vibegron

More information about this Drug

Patents Expiration Date
US8653260 April 2, 2029
US8247415 December 1, 2030

Dosage: Oral
Company: Urovant Sciences Gmbh
Ingredients: VIBEGRON
Treatment: Overactive Bladder

Kerendia
Finerenone

More information about this Drug

Patents Expiration Date
US8436180 April 12, 2029

Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals Inc
Ingredients: FINERENONE
Treatment: Kidney Function

Triferic
Ferric Pyrophosphate Citrate

More information about this Drug

Patents Expiration Date
US7816404 April 17, 2029

Dosage: Intravenous
Company: Rockwell Medical Inc
Ingredients: FERRIC PYROPHOSPHATE CITRATE
Treatment: Iron Deficiency Anemia

Cipro
Ciprofloxacine

More information about this Drug

Patents Expiration Date
US9603796 April 21, 2029

Dosage: Oral, Intravenous, Topical
Company: Alk-abello Inc
Ingredients: CIPROFLOXACIN
Treatment: Bacterial Infections

Veklury
Remdesivir

More information about this Drug

Patents Expiration Date
USRE46762 April 22, 2029
US8318682 April 22, 2029
US8008264 September 6, 2029
US10065958 September 16, 2031
US9724360 October 29, 2035
US9949994 October 29, 2035

Dosage: Intravenous
Company: Gilead Sciences Inc
Ingredients: REMDESIVIR
Treatment: Antiviral

Zejula
Niraparib

More information about this Drug

Patents Expiration Date
US8436185 April 24, 2029
US8071623 March 27, 2031

Dosage: Oral
Company: GlaxoSmithKline Llc
Ingredients: NIRAPARIB TOSYLATE
Treatment: Anti-cancer

Zeposia
Ozanimod

More information about this Drug

Patents Expiration Date
US8481573 May 14, 2029
US8796318 May 14, 2029

Dosage: Oral
Company: Celgene International Ii Sarl
Ingredients: OZANIMOD HYDROCHLORIDE
Treatment: Multiple Sclerosis And Ulcerative Colitis

Tauvid
Flortaucipir (18F)

More information about this Drug

Patents Expiration Date
US8932557 May 19, 2029

Dosage: Intravenous
Company: Avid Radiopharmaceuticals Inc
Ingredients: FLORTAUCIPIR F-18
Treatment: Radioactive Diagnostic Agent

Opana Er
Oxymorphone

More information about this Drug

Patents Expiration Date
US7851482 July 10, 2029
US8871779 November 22, 2029

Dosage: Oral
Company: Endo Pharmaceuticals Inc
Ingredients: OXYMORPHONE HYDROCHLORIDE
Treatment: Severe Pain

Braftovi
Encorafenib

More information about this Drug

Patents Expiration Date
US8946250 July 23, 2029
US8541575 February 26, 2030
US9593099 August 27, 2030
US8501758 March 4, 2031

Dosage: Oral
Company: Array Biopharma Inc
Ingredients: ENCORAFENIB
Treatment: Melanoma

Odomzo
Sonidegib

More information about this Drug

Patents Expiration Date
US8178563 July 24, 2029
US8063043 September 15, 2029

Dosage: Oral
Company: Sun Pharmaceutical Industries Ltd
Ingredients: SONIDEGIB PHOSPHATE
Treatment: Cancer

Zepatier
Elbasvir/Grazoprevir

More information about this Drug

Patents Expiration Date
US7973040 July 24, 2029
US8871759 May 4, 2031

Dosage: Oral
Company: Merck Sharp And Dohme Corp
Ingredients: ELBASVIR; GRAZOPREVIR
Treatment: Hepatitis C

Talzenna
Talazoparib

More information about this Drug

Patents Expiration Date
US8420650 July 27, 2029
US8012976 October 19, 2029
US10189837 October 20, 2031
US8735392 October 20, 2031

Dosage: Oral
Company: Pfizer Inc
Ingredients: TALAZOPARIB TOSYLATE
Treatment: Breast Cancer

Evotaz
Atazanavir/Cobicistat

More information about this Drug

Patents Expiration Date
US8148374 September 3, 2029

Dosage: Oral
Company: Bristol-Myers Squibb Co
Ingredients: ATAZANAVIR SULFATE; COBICISTAT
Treatment: HIV/AIDS

Piqray
Alpelisib

More information about this Drug

Patents Expiration Date
US8476268 September 10, 2029
US8227462 September 28, 2030

Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: ALPELISIB
Treatment: Breast Cancer

Tykerb
Lapatinib

More information about this Drug

Patents Expiration Date
US8821927 September 18, 2029

Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: LAPATINIB DITOSYLATE
Treatment: Breast Cancer

Treanda
Bendamustine

More information about this Drug

Patents Expiration Date
US8445524 September 26, 2029

Dosage: Intravenous
Company: Cephalon Inc
Ingredients: BENDAMUSTINE HYDROCHLORIDE
Treatment: Chronic Lymphocytic Leukemia, Multiple Myeloma, And Non-Hodgkin’s Lymphoma

Ingrezza
Valbenazine

More information about this Drug

Patents Expiration Date
US8039627 October 6, 2029
US10065952 October 28, 2036
US10844058 October 28, 2036
US10851103 October 28, 2036
US10851104 October 28, 2036
US10906902 December 22, 2036
US10919892 December 22, 2036
US10906903 December 22, 2036

Dosage: Intravenous
Company: Neurocrine Biosciences Inc
Ingredients: VALBENAZINE TOSYLATE
Treatment: Tardive Dyskinesia

Vitrakvi
Larotrectinib

More information about this Drug

Patents Expiration Date
US9127013 October 21, 2029
US8513263 December 23, 2029
US10172861 November 16, 2035
US10799505 August 15, 2036

Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals Inc
Ingredients: LAROTRECTINIB SULFATE
Treatment: Cancer

Rezurock
Belumosudil

More information about this Drug

Patents Expiration Date
US8357693 October 30, 2029

Dosage: Oral
Company: Kadmon Pharmaceuticals Llc
Ingredients: BELUMOSUDIL MESYLATE
Treatment: Chronic Graft Versus Host Disease

Cotellic
Cobimetinib

More information about this Drug

Patents Expiration Date
US7803839 November 10, 2029
US10478400 June 29, 2036/td>
US10590102 June 30, 2036

Dosage: Oral
Company: Genentech Inc
Ingredients: COBIMETINIB FUMARATE
Treatment: Anti-cancer

Recarbrio
Imipenem/Cilastatin/Relebactam

More information about this Drug

Patents Expiration Date
US8487093 November 19, 2029

Dosage: Intravenous
Company: Merck Sharp And Dohme 
Ingredients: CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Treatment: Urinary Tract And Complicated Intra-abdominal Infections

Belsomra
Suvorexant

More information about this Drug

Patents Expiration Date
US7951797 November 20, 2029

Dosage: Oral
Company: Merck Sharp And Dohme 
Ingredients: SUVOREXANT
Treatment: Insomnia

Verzenio
Abemaciclib

More information about this Drug

Patents Expiration Date
US7855211 December 15, 2029

Dosage: Oral
Company: Eli Lilly And Co
Ingredients: ABEMACICLIB
Treatment: Breast Cancers

Tavneos
Avacopan

More information about this Drug

Patents Expiration Date
US8906938 December 21, 2029
US8445515 February 3, 2031

Dosage: Oral
Company: Chemocentryx Inc
Ingredients: AVACOPAN
Treatment: Anti-neutrophil Cytoplasmic Auto antibody-associated Vasculitis

Ibsrela
Tenapanor

More information about this Drug

Patents Expiration Date
US8541448 December 30, 2029
US8969377 December 30, 2029

Dosage: Oral
Company: Ardelyx Inc
Ingredients: TENAPANOR HYDROCHLORIDE
Treatment: Irritable Bowel Syndrome

Eucrisa
Crisaborole

More information about this Drug

Patents Expiration Date
US8039451 December 29, 2029

Dosage: Topical
Company: Anacor Pharmaceuticals Inc
Ingredients: CRISABOROLE
Treatment: Atopic Dermatitis

With the huge growth in the generic drug market, it has become essential for generic companies like yours to keep a tab on the drugs with a soon-to-be-expired label. But that’s not enough, you have to stay ahead of your competitors too. This is where GreyB comes in!

Our pharma team is working on its toes to extract all the drug patents expiring in the next 8 years from now. Want to get your hands on the complete list?

Get in touch

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.